TWI328006B - Crystal form of quinoline compound and process for its production - Google Patents
Crystal form of quinoline compound and process for its production Download PDFInfo
- Publication number
- TWI328006B TWI328006B TW093136780A TW93136780A TWI328006B TW I328006 B TWI328006 B TW I328006B TW 093136780 A TW093136780 A TW 093136780A TW 93136780 A TW93136780 A TW 93136780A TW I328006 B TWI328006 B TW I328006B
- Authority
- TW
- Taiwan
- Prior art keywords
- crystal form
- production
- quinoline compound
- stability
- drug substance
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- -1 quinoline compound Chemical class 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 229940088679 drug related substance Drugs 0.000 abstract 2
- 229960003296 pitavastatin calcium Drugs 0.000 abstract 2
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003431788 | 2003-12-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200530186A TW200530186A (en) | 2005-09-16 |
| TWI328006B true TWI328006B (en) | 2010-08-01 |
Family
ID=34736450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093136780A TWI328006B (en) | 2003-12-26 | 2004-11-29 | Crystal form of quinoline compound and process for its production |
Country Status (21)
| Country | Link |
|---|---|
| US (19) | US20070112024A1 (enExample) |
| EP (1) | EP1697326B1 (enExample) |
| JP (7) | JP5186108B2 (enExample) |
| KR (11) | KR20190083674A (enExample) |
| CN (2) | CN1898211A (enExample) |
| AT (1) | ATE518835T1 (enExample) |
| AU (2) | AU2004309241A1 (enExample) |
| CA (1) | CA2551050C (enExample) |
| CY (1) | CY1112464T1 (enExample) |
| DK (1) | DK1697326T3 (enExample) |
| ES (1) | ES2367172T3 (enExample) |
| IL (1) | IL176470A (enExample) |
| MX (1) | MX338019B (enExample) |
| NZ (1) | NZ548041A (enExample) |
| PL (1) | PL1697326T3 (enExample) |
| PT (1) | PT1697326E (enExample) |
| RU (1) | RU2370489C2 (enExample) |
| SI (1) | SI1697326T1 (enExample) |
| TW (1) | TWI328006B (enExample) |
| WO (1) | WO2005063711A1 (enExample) |
| ZA (1) | ZA200605658B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004072040A1 (en) | 2003-02-12 | 2004-08-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of pitavastatin calcium |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| US7801272B2 (en) * | 2007-09-28 | 2010-09-21 | Rigaku Corporation | X-ray diffraction apparatus and X-ray diffraction method |
| US20120022102A1 (en) * | 2010-01-20 | 2012-01-26 | Cadila Healthcare Limited | Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof |
| KR101158517B1 (ko) | 2010-04-29 | 2012-06-21 | 동방에프티엘(주) | 고 순도 피타바스타틴 칼슘염 결정형 ａ의 제조방법 |
| JP2013536219A (ja) * | 2010-08-25 | 2013-09-19 | カディラ・ヘルスケア・リミテッド | ピタバスタチンカルシウムおよびその調製方法 |
| WO2012063254A1 (en) | 2010-11-12 | 2012-05-18 | Hetero Research Foundation | Novel polymorphs of pitavastatin calcium |
| RU2452939C1 (ru) * | 2011-01-18 | 2012-06-10 | Закрытое акционерное общество "Научные приборы" | Рентгенодифракционный способ идентификации партий фармацевтической продукции |
| ITMI20111475A1 (it) * | 2011-08-02 | 2013-02-03 | Dipharma Francis Srl | Forme cristalline di pitavastatina sale di calcio |
| WO2013037838A1 (en) | 2011-09-12 | 2013-03-21 | Farma Grs, D.O.O. | Polymorphic form of pitavastatin calcium |
| WO2013098773A1 (en) * | 2011-12-28 | 2013-07-04 | Dr. Reddy's Laboratories Limited | Crystalline forms of pitavastatin calcium |
| JP5190159B1 (ja) * | 2012-08-08 | 2013-04-24 | 興和株式会社 | 医薬 |
| CN104507949B (zh) * | 2012-09-27 | 2017-07-28 | 日产化学工业株式会社 | 高纯度的含氮杂环化合物的制造方法 |
| JP2014034574A (ja) * | 2013-01-25 | 2014-02-24 | Kowa Company Ltd | 医薬 |
| EP2970128B1 (en) * | 2013-03-15 | 2019-12-04 | Asieris Pharmaceutical Technologies Co., Ltd. | Base addition salts of nitroxoline and uses thereof |
| CN105213319A (zh) * | 2015-09-17 | 2016-01-06 | 青岛华之草医药科技有限公司 | 一种降血脂药物匹伐他汀钙组合物干混悬剂 |
| JP2016222714A (ja) * | 2016-09-20 | 2016-12-28 | 興和株式会社 | 医薬 |
| TW202200547A (zh) * | 2020-03-13 | 2022-01-01 | 印度商卡地拉保健有限公司 | 喹啉酮化合物的新穎鹽類 |
| EP4308089A4 (en) * | 2021-03-19 | 2025-02-26 | Zydus Lifesciences Limited | QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THEIR PREPARATION |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3175944A (en) * | 1956-06-18 | 1965-03-30 | Upjohn Co | Dihydronovobiocin and derivatives thereof |
| IL63968A (en) | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
| GB8320521D0 (en) * | 1983-07-29 | 1983-09-01 | Glaxo Group Ltd | Chemical process |
| JPS61171460A (ja) * | 1985-01-23 | 1986-08-02 | Dainippon Pharmaceut Co Ltd | 塩酸メクロフエノキサ−ト１型結晶の製造法 |
| JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
| JP2877366B2 (ja) | 1988-08-25 | 1999-03-31 | 協和醗酵工業株式会社 | 結晶状ｌ−アスコルビン酸−２−リン酸ナトリウム塩の製造法 |
| JP3528186B2 (ja) * | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
| JPH0613526A (ja) | 1992-06-25 | 1994-01-21 | Seiko Epson Corp | 半導体装置用リードフレーム及びその製造方法 |
| JP2575590B2 (ja) * | 1992-07-31 | 1997-01-29 | 塩野義製薬株式会社 | トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法 |
| FR2694558B1 (fr) | 1992-08-05 | 1994-10-28 | Sanofi Elf | Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant. |
| DE4235133A1 (de) | 1992-10-19 | 1994-04-21 | Bayer Ag | Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid |
| JP3623531B2 (ja) | 1993-06-07 | 2005-02-23 | ビーエーエスエフ アクチェンゲゼルシャフト | 結晶質ｌ−アスコルビン酸−２−燐酸エステルマグネシウム塩の製造法 |
| JP3558684B2 (ja) * | 1994-06-28 | 2004-08-25 | 塩野義製薬株式会社 | ピロリジルチオカルバペネム誘導体の乾燥方法 |
| NZ512207A (en) * | 1999-01-14 | 2002-10-25 | Nissan Chemical Ind Ltd | Process for producing quinolinecarbaldehyde |
| CA2450820C (en) * | 2001-08-16 | 2011-03-15 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
| US6835838B2 (en) | 2002-01-28 | 2004-12-28 | Novartis Ag | Process for the manufacture of organic compounds |
| DE60326819D1 (de) * | 2002-01-31 | 2009-05-07 | Novartis Ag | Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase |
| US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| US20050130978A1 (en) * | 2002-04-17 | 2005-06-16 | Masamichi Yuda | Novel crystal of quinoxalinedione derivative anhydride |
| WO2004072040A1 (en) * | 2003-02-12 | 2004-08-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of pitavastatin calcium |
| TWI328006B (en) | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
-
2004
- 2004-11-29 TW TW093136780A patent/TWI328006B/zh not_active IP Right Cessation
- 2004-12-17 ZA ZA200605658A patent/ZA200605658B/en unknown
- 2004-12-17 WO PCT/JP2004/019451 patent/WO2005063711A1/en not_active Ceased
- 2004-12-17 US US10/584,208 patent/US20070112024A1/en not_active Abandoned
- 2004-12-17 KR KR1020197019411A patent/KR20190083674A/ko not_active Withdrawn
- 2004-12-17 KR KR1020177001565A patent/KR20170010111A/ko not_active Withdrawn
- 2004-12-17 KR KR1020167016139A patent/KR20160075844A/ko not_active Withdrawn
- 2004-12-17 KR KR1020177023135A patent/KR20170098976A/ko not_active Withdrawn
- 2004-12-17 CN CNA2004800389550A patent/CN1898211A/zh active Pending
- 2004-12-17 RU RU2006127044/04A patent/RU2370489C2/ru not_active Application Discontinuation
- 2004-12-17 KR KR1020207003201A patent/KR20200015826A/ko not_active Withdrawn
- 2004-12-17 SI SI200431760T patent/SI1697326T1/sl unknown
- 2004-12-17 KR KR1020117002847A patent/KR20110017936A/ko not_active Ceased
- 2004-12-17 JP JP2006520594A patent/JP5186108B2/ja not_active Expired - Lifetime
- 2004-12-17 KR KR1020187010082A patent/KR20180040732A/ko not_active Withdrawn
- 2004-12-17 KR KR1020207032499A patent/KR20200130510A/ko not_active Ceased
- 2004-12-17 PL PL04807807T patent/PL1697326T3/pl unknown
- 2004-12-17 KR KR1020067011877A patent/KR20070001910A/ko not_active Ceased
- 2004-12-17 EP EP04807807A patent/EP1697326B1/en not_active Expired - Lifetime
- 2004-12-17 MX MX2011007418A patent/MX338019B/es unknown
- 2004-12-17 KR KR1020137001739A patent/KR20130014643A/ko not_active Withdrawn
- 2004-12-17 PT PT04807807T patent/PT1697326E/pt unknown
- 2004-12-17 NZ NZ548041A patent/NZ548041A/en not_active IP Right Cessation
- 2004-12-17 DK DK04807807.5T patent/DK1697326T3/da active
- 2004-12-17 CN CN201110198613.7A patent/CN102321019B/zh not_active Expired - Lifetime
- 2004-12-17 ES ES04807807T patent/ES2367172T3/es not_active Expired - Lifetime
- 2004-12-17 CA CA2551050A patent/CA2551050C/en not_active Expired - Lifetime
- 2004-12-17 AT AT04807807T patent/ATE518835T1/de active
- 2004-12-17 AU AU2004309241A patent/AU2004309241A1/en not_active Abandoned
- 2004-12-17 KR KR1020187035028A patent/KR20180132973A/ko not_active Withdrawn
-
2006
- 2006-06-21 IL IL176470A patent/IL176470A/en active IP Right Grant
-
2009
- 2009-03-11 US US12/401,945 patent/US20090176987A1/en not_active Abandoned
-
2010
- 2010-12-13 US US12/966,102 patent/US20110082298A1/en not_active Abandoned
-
2011
- 2011-08-18 AU AU2011213742A patent/AU2011213742C1/en not_active Expired
- 2011-09-07 US US13/227,003 patent/US20110319624A1/en not_active Abandoned
- 2011-10-20 CY CY20111100995T patent/CY1112464T1/el unknown
- 2011-11-29 JP JP2011260984A patent/JP5267643B2/ja not_active Expired - Lifetime
-
2012
- 2012-06-04 US US13/487,289 patent/US20120245200A1/en not_active Abandoned
-
2013
- 2013-03-15 US US13/832,285 patent/US20130204000A1/en not_active Abandoned
- 2013-04-05 JP JP2013079889A patent/JP2013136640A/ja not_active Withdrawn
- 2013-10-30 US US14/066,762 patent/US20140058109A1/en not_active Abandoned
-
2014
- 2014-03-21 US US14/221,372 patent/US20140206719A1/en not_active Abandoned
- 2014-08-01 JP JP2014157888A patent/JP2014205719A/ja not_active Withdrawn
-
2015
- 2015-02-18 US US14/625,046 patent/US20150158816A1/en not_active Abandoned
- 2015-11-16 JP JP2015224264A patent/JP2016029102A/ja not_active Withdrawn
-
2016
- 2016-09-15 US US15/266,095 patent/US20170226061A1/en not_active Abandoned
- 2016-11-22 JP JP2016227123A patent/JP2017061536A/ja not_active Withdrawn
-
2017
- 2017-11-15 US US15/813,422 patent/US20180072676A1/en not_active Abandoned
-
2018
- 2018-01-10 JP JP2018002103A patent/JP2018052988A/ja not_active Withdrawn
- 2018-06-19 US US16/011,870 patent/US20180297956A1/en not_active Abandoned
-
2019
- 2019-01-24 US US16/256,070 patent/US20190152916A1/en not_active Abandoned
- 2019-08-19 US US16/543,653 patent/US20190367458A1/en not_active Abandoned
-
2020
- 2020-03-16 US US16/819,317 patent/US20200216395A1/en not_active Abandoned
- 2020-11-05 US US17/090,353 patent/US20210053923A1/en not_active Abandoned
-
2022
- 2022-02-28 US US17/682,065 patent/US20220177433A1/en not_active Abandoned
-
2023
- 2023-06-14 US US18/334,683 patent/US20230322679A1/en not_active Abandoned
-
2024
- 2024-04-17 US US18/637,529 patent/US20240294476A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL176470A0 (en) | Crystal form of quinoline compound and process for its production | |
| CY1111327T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος | |
| GEP20074135B (en) | Process for the synthesis of (is)-4,5-dimethoxy-1-(methylaminomethyl)- benzocyclobutane and addition salts thereof, and to the application thereof in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| LV12735A (en) | Manufacture and pharmaceutical compositions thereof | |
| MXPA05013752A (es) | Procedimiento e intermediarios para la preparacion de (1r,2s,5s)-6,6-dimetil-3-azabiciclo[3,1,0]exan-2-carboxilatos o sales de los mismos. | |
| HUP0301022A2 (hu) | Tiotropinium-bromid-monohidrát, eljárás előállítására és alkalmazása gyógyszerkészítmény előállítására | |
| MX2007006311A (es) | Acidos hidroxibifenilcarboxilicos y derivados, metodo para producirlos y su uso. | |
| CA2793138C (en) | Hydroxybenzoate salts of metanicotine compounds | |
| BG106389A (en) | Crystals of the sodium salt of pravastatin | |
| YU24001A (sh) | Nova kristalna modifikacija torasemida | |
| SI1745010T1 (sl) | Substituirani cikloheksil-1,4-diaminski derivati | |
| NO20055694L (no) | Fremgangsmate for fremstilling av (4-hydroksy-6-oksotetrahydropyran-2-yl)acetonitril og derivater derav | |
| GB0417063D0 (en) | Process for the preparation of optically-active compounds | |
| CN105153118A (zh) | 一种甲磺酸达比加群酯制备过程中中间体的中控方法 | |
| ATE270296T1 (de) | Verfahren zur herstellung von hochkristallinem natrium cefoperazon | |
| NZ589496A (en) | Processes and compounds for the preparation of normorphinans | |
| AP2002002587A0 (en) | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith. | |
| ATE466010T1 (de) | Verfahren zur herstellung von candesartan | |
| DE602005013007D1 (de) | Verfahren zur herstellung von lactonen | |
| TW200611901A (en) | Method for producing 1, 3-dioxolan-4, 6-dione compound | |
| EP1765350A4 (en) | METHOD OF MANUFACTURING A SOLID DISPERSION WITH ITRACONAZOLE | |
| NO20060922L (no) | Ny fremgangsmate for syntesen av perindopril og dens farmasoytiske akseptable salter | |
| MX2022006569A (es) | Proceso para la sintesis de una 2-tioalquilpirimidina. | |
| ATE309226T1 (de) | Verfahren zur herstellung von fluconazole und kristallmodifikationen davon | |
| SG164282A1 (en) | Taxane derivatives functionalized at the 14-position and a process for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MC4A | Revocation of granted patent |